250 related articles for article (PubMed ID: 23598909)
1. Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches.
Galsky MD; Domingo-Domenech J
Clin Adv Hematol Oncol; 2013 Feb; 11(2):86-92. PubMed ID: 23598909
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer.
Clark PE
Expert Rev Anticancer Ther; 2009 Jun; 9(6):821-30. PubMed ID: 19496719
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy: a new treatment paradigm for muscle-invasive bladder cancer.
Herr HW
Eur Urol; 2009 Feb; 55(2):303-5; discussion 305-6. PubMed ID: 18995950
[No Abstract] [Full Text] [Related]
4. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
Stenzl A; Cowan NC; De Santis M; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
Eur Urol; 2011 Jun; 59(6):1009-18. PubMed ID: 21454009
[TBL] [Abstract][Full Text] [Related]
5. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
Raj GV; Karavadia S; Schlomer B; Arriaga Y; Lotan Y; Sagalowsky A; Frenkel E
Cancer; 2011 Jan; 117(2):276-82. PubMed ID: 20830767
[TBL] [Abstract][Full Text] [Related]
6. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
7. Selective organ preservation in muscle-invasive bladder cancer: review of the literature.
Khosravi-Shahi P; Cabezón-Gutiérrez L
Surg Oncol; 2012 Mar; 21(1):e17-22. PubMed ID: 22088598
[TBL] [Abstract][Full Text] [Related]
8. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.
Milowsky MI; Stadler WM; Bajorin DF
BJU Int; 2008 Nov; 102(9 Pt B):1339-44. PubMed ID: 19035902
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argument in favor.
Gallagher DJ; Bajorin DF
Nat Clin Pract Urol; 2008 Sep; 5(9):484-5. PubMed ID: 18626513
[No Abstract] [Full Text] [Related]
10. [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].
Stenzl A; Cowan NC; De Santis M; Jakse G; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
Actas Urol Esp; 2010 Jan; 34(1):51-62. PubMed ID: 20223133
[TBL] [Abstract][Full Text] [Related]
11. Management of muscle-invasive bladder cancer: an update.
Ghoneim MA; Abol-Enein H
Nat Clin Pract Urol; 2008 Sep; 5(9):501-8. PubMed ID: 18769377
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer.
Calabrò F; Sternberg CN
Eur Urol; 2009 Feb; 55(2):348-58. PubMed ID: 18977070
[TBL] [Abstract][Full Text] [Related]
13. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer: bridging the gap between evidence and practice.
Sfakianos JP; Galsky MD
Urol Clin North Am; 2015 May; 42(2):181-7, viii. PubMed ID: 25882560
[TBL] [Abstract][Full Text] [Related]
15. CKD-EPI and cockcroft-gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Pal SK; Ruel N; Villegas S; Chang M; DeWalt K; Wilson TG; Vogelzang NJ; Yuh BE
PLoS One; 2014; 9(4):e94471. PubMed ID: 24722472
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy in patients with invasive bladder cancer.
Vaughn DJ; Malkowicz SB
Urol Clin North Am; 2005 May; 32(2):231-7. PubMed ID: 15862620
[TBL] [Abstract][Full Text] [Related]
19. Defining optimal therapy for muscle invasive bladder cancer.
Herr HW; Dotan Z; Donat SM; Bajorin DF
J Urol; 2007 Feb; 177(2):437-43. PubMed ID: 17222605
[TBL] [Abstract][Full Text] [Related]
20. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ-preserving therapy in carefully selected patients.
Heidenreich A
Eur Urol; 2008 Jul; 54(1):21-3. PubMed ID: 18262722
[No Abstract] [Full Text] [Related]
[Next] [New Search]
